glp-1 parkinson's disease lancet Beyond insulin: The Intriguing role

When Lower Doses May Be Clinically Discussed Some clinicians may consider individualized dose adjustments in situations such as: Significant gastrointestinal intolerance Gradual re-initiation after interruption Unique patient-specific clinical considerations These decisions are individualized and should not be made independently

That means a clinician should review whether a patient has a history of relevant endocrine issues, pancreatitis, gallbladder problems, kidney concerns, chronic GI symptoms, or other conditions that may affect safety or treatment choice

This product is not classified as a drug, food, or cosmetic

What Are GLP1 Receptor Agonist Injections

Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor

It does mean the science is moving toward a broader view of GLP-1s as metabolic regulators, not just obesity drugs